pp 1–9 | Cite as

Identification of potential inhibitors targeted for strengthening search of anti-leishmanial therapeutics

  • Anubhuti Jha
  • Stuti Verma
  • Awanish KumarEmail author
Original Article


Visceral leishmaniasis (VL: a fatal disease) is reported to occur at the rate of 70,000 to 90,000 per year, according to WHO. VL is caused by Leishmania donovani species causing 90% cases of VL. Current treatment regime is not satisfactory due to substantial toxic side effects of existing antileishmanial therapy and the emergence of drug resistance from different part of the world. These issues make existing therapy unsuitable management of VL. There are various studies dedicated to overcoming the shortcomings in antileishmanial therapeutics. Likewise, in this study, we have targeted HSP100 (heat shock protein) of L. donovani for identification of potent antileishmanial. HSP100 protein is released when the Leishmania parasite encounters heat stress in macrophage of mammalian host making it an effective target. This in silico study was carried out with 10 unexplored ligands and Miltefosine (an established anti-leishmanial drug used as control) via targeting L. donovani HSP100. We report that two test ligands Diospyrin and Benzoxaborole had outstanding docking potential with L. donovani HSP100 and were chosen for further analysis of drug-likeness and ADMET (absorption distribution, metabolism, and excretion) properties. These two ligands docking scores were better than the antileishmanial Miltefosine and had better ADMET properties as a drug candidate. The result gave us a lead and confirmation to support our hypothesis that HSP100 can be a potential drug target of L. donovani and Diospyrin and Benzoxaborole can be potent antileishmanial molecules.


Leishmania donovani HSP100 Diospyrin Benzoxaborole Potent antileishmanial 



Visceral Leishmaniasis


Heat shock protein


Comprehensive medical chemistry


Modern drug data report


World drug Index


Absorption distribution, metabolism and excretion


Madin Darby canine kidney


human ether a go-go inhibition



Authors are thankful to the Department of Biotechnology, National Institute of Technology Raipur (CG), India for providing facility, space, and resources for this work.

Compliance with ethical standards

Conflict of interest



  1. Darcis G, Van der Auwera G, Giot J-B et al (2017) Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC Infect Dis 17:478. CrossRefPubMedPubMedCentralGoogle Scholar
  2. de Melo EC, Fortaleza CMCB (2013) Challenges in the therapy of visceral leishmaniasis in Brazil: a public health perspective. J Trop Med 2013:319234. CrossRefPubMedPubMedCentralGoogle Scholar
  3. Doehl JSP, Bright Z, Dey S et al (2017) Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nat Commun 8:57. CrossRefPubMedPubMedCentralGoogle Scholar
  4. Ekins S, Rose J (2002) In silico ADME/Tox: the state of the art. J Mol Graph Model 20:305–309. CrossRefPubMedGoogle Scholar
  5. Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49:377–389. CrossRefPubMedGoogle Scholar
  6. Jessen L, Bard B, Grenon X, Bally F (2016) Leishmaniasis : an infection of travellers and migrants. Rev Med Suisse 12:1718–1722PubMedGoogle Scholar
  7. Jha A, Kumar A (2016) Development and targeting of transcriptional regulatory network controlling FLU1 activation in Candida albicans for novel antifungals. J Mol Graph Model 69:1–7. CrossRefPubMedGoogle Scholar
  8. Jha A, Kumar A (2018) Deciphering the role of sodium lignosulfonate against Candida spp. as persuasive anticandidal agent. Int J Biol Macromol 107:1212–1219. CrossRefPubMedGoogle Scholar
  9. Jha A, Kumar A (2019) Multiple drug targeting potential of novel ligands against virulent proteins of Candida albicans. Int J Pept Res Ther:1–22.
  10. Jha A, Vimal A, Bakht A, Kumar A (2018) Inhibitors of CPH1-MAP kinase pathway: ascertaining potential ligands as multi-target drug candidate in Candida albicans. Int J Pept Res Ther:1–14.
  11. Kim LS, Kim JH (2011) Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer 14:167–174. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Krobitsch S, Brandau S, Hoyer C et al (1998) Leishmania donovani heat shock protein 100. Characterization and function in amastigote stage differentiation. J Biol Chem 273:6488–6494CrossRefGoogle Scholar
  13. Pandey SC, Jha A, Kumar A, Samant M (2019) Evaluation of antileishmanial potential of computationally screened compounds targeting DEAD-box RNA helicase of Leishmania donovani. Int J Biol Macromol 121:480–487. CrossRefPubMedGoogle Scholar
  14. Peng QX, Guan XH, Yi ZG, Su YP (2014) Insilico approaches in anesthetic drug development: Computer aided drug designing. Drug Res (Stuttg) 8.
  15. Romero GAS, Costa DL, Costa CHN et al (2017) Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: a multicenter, randomized, open label trial. PLoS Negl Trop Dis 11:e0005706. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Singh S, Sivakumar R (2004) Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother 10:307–315. CrossRefPubMedGoogle Scholar
  17. Singh A, Kaushik R, Mishra A et al (2016) ProTSAV: a protein tertiary structure analysis and validation server. Biochim Biophys Acta - Proteins Proteomics 1864:11–19. CrossRefGoogle Scholar
  18. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R (2017) Leishmaniasis: a review. F1000Research 6:750. CrossRefPubMedPubMedCentralGoogle Scholar
  19. Tubert-Brohman I, Sherman W, Repasky M, Beuming T (2013) Improved docking of polypeptides with glide. J Chem Inf Model 53:1689–1699. CrossRefPubMedGoogle Scholar

Copyright information

© Institute of Molecular Biology, Slovak Academy of Sciences 2019

Authors and Affiliations

  1. 1.Department of BiotechnologyNational Institute of Technology RaipurRaipurIndia

Personalised recommendations